Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228752 | 0.88 | PRKAB2 (0.35) | AQP1CA2AURKAGSK3AGSK3B | |
| SCHEMBL8221231 | 0.81 | AQP1 (0.41) | AQP1CA2CYP19A1 | |
| SCHEMBL8220457 | 0.80 | AQP1 (0.42) | AQP1CA2CYP19A1 | |
| SCHEMBL8220449 | 0.80 | SLC6A4 (0.43) | AQP1CA2 | |
| SCHEMBL8202938 | 0.80 | AQP1 (0.47) | AQP1KLKB1PRMT5WDR77 | |
| SCHEMBL8225835 | 0.79 | AQP1 (0.43) | AQP1CA2FFAR1CYP19A1 | |
| SCHEMBL3207048 | 0.79 | AQP1 (0.39) | AQP1GSK3AGSK3BKLKB1PRMT5 | |
| SCHEMBL3207355 | 0.79 | AQP1 (0.39) | AQP1GSK3AGSK3BKLKB1PRMT5 | |
| SCHEMBL3216292 | 0.79 | AQP1 (0.39) | AQP1GSK3AGSK3BKLKB1PRMT5 | |
| SCHEMBL8220451 | 0.78 | SLC6A2 (0.46) | AQP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | AQP1 1697/4885CA2 4153/4885AURKA 4854/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | AQP1 2199/4885CA2 2702/4885AURKA 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.